BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer

2014229 citationsJournal Articlegreen Open Access

Authors

Dabrafenib was well tolerated and resulted in durable responses in BRAF-mutant differentiated thyroid carcinoma patients.

Good health and well-being

Published in: Thyroid

Volume 25, Issue 1, pp. 71-77

Field-Weighted Citation Impact: 10.94